瑞舒伐他汀对ACS患者血清TF的影响

目的：研究瑞舒伐他汀对急性冠脉综合征（acutecoronarysyndrome,ACS）患者血清组织因子（tissuefactor,TF）的影响。方法：体外试验,取10例ACS患者空腹外周静脉血分离、培养人单核细胞,予以治疗后浓度为0、0.1、1、10μmol/L的瑞舒伐他汀进行干预,用酶联免疫吸附法检测培养细胞膜TF水平。临床试验,选取28例ACS患者根据服用药物情况分为未用药物组、瑞舒伐他汀治疗组各14例,检测外周血中TF含量,同时检测血脂、血糖、胰岛素、C肽、C反应蛋白等相关指标。结果：瑞舒伐他汀组在0、0.1、1、10μmol/L浓度时TF测定值分别为（6.89±1.07）、（4.08±0.69）、（3.78±0.65）、（1.99±0.65）pg/ml;在28例ACS患者外周中,瑞舒伐他汀组与未用药物干预组TF分别为（88.25±21.55）、（210.28±95.42）pg/ml,P〈0.05,差异有统计学意义。结论：瑞舒伐他汀可降低ACS外周血单核细胞合成TF的表达,并呈现浓度依赖性,同时可改善血脂异常,提高胰岛素敏感性,降低ACS患者循环血中TF的表达。

Influnce of Rosuvastatin on TF in patients with ACS

Objective： To study the effect of Rosuvastatin on serum tissue factor （TF） in patients with acute coronary syndrome （ACS）. Methods： Both in-vitro experiment and clinical trials were performed. In in-vitro experiment, mononuclear cells in the fasting peripheral venous blood sample of 10 patients were isolated and cultured. The cell cultures were given Rosuvastatin of after-treatment concentration of 0, 0.1, 1 and 10 μmol/L. TF levels of the cells were tested with enzyme-linked immunosorbent assay. In clinical trial, 28 patients with ACS were assigned randomly to control group and Rosuvastatin treatment group 14 cases each group. After treatment, TF level, serum lipids, blood glucose, insulin, C-peptide, C-reactive protein and other related indicators of peripheral blood were tested. Results： TF results of different Rosuvastatin concentrations 0, 0.1,1,10 μmol/L were （6.89±1.07）, （4.08±0.69）, （3.78±0.65） and （1.99±0.65） pg/ml respectively in in-vitro experiment. In clinical trial, TF results of control group and treatment group were significantly different （P0.05） and were （88.25±21.55）, （210.28±95.42） pg/ml respectively. Conclusion： Rosuvastatin can reduce TF expression of mononuclear cells in peripheral blood of ACS patients and the effect is concentration dependent. It can also improve dyslipidemia, increase insulin sensitivity and reduce TF expression in circulating blood in ACS patients.